V.TLT | June 19, 2024
x x x Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model.
x x x The mice treated with x-ray activated Rutherrin® demonstrated up to a 4-fold reduced tumor progression, based on Computerized Tomography (“CT”) scan assessment of tumor volumes.
As shown in Figure 1, there was a significant delay in tumor progression in mice treated with x-ray activated Rutherrin® versus radiation (x-ray) alone (p> 0.001). In fact, in mice treated with x-ray activated Rutherrin®, the tumour is notably regressing / being destroyed over time.
x x x
These results demonstrate that animals treated with a combination of Rutherrin® and radiation therapy showed an increase in median survival from 26 to 35 days, versus radiation only. In scientific publications, mouse survival of 9 days has been equated to the equivalent of 1 year survival in humans, but more importantly, is that one animal treated with the x-ray activated Rutherrin® (which had a positive lung tumor verified by CT scan) demonstrated a complete response and is now considered cancer free.
RDW: "x x x If proven safe and effective in humans, Theralase® hopes to change the paradigm of how patients diagnosed with cancer are treated in the future.”
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically – Theralase Technologies